Case Study 2 — Compounded Semaglutide

What happens when the hype cycle attaches itself to a drug that actually works

Type: Real, public, recent · Tier 1 regulatory facts, Tier 2 market detail · Relevance: §6.1, §6.4, §6.7 · The anchor case, opened here and completed in Chapters 12, 19, 34, and 38

Background: the shortage

Semaglutide worked. That is where this story starts, and it matters, because every previous case in this chapter has involved a compound whose human evidence was thin or absent. This one has a Phase III program, multiple approvals, and a cardiovascular outcomes trial.

Demand exceeded anything the manufacturer had planned for. The constraint was not the peptide — Chapter 4 established that the binding limitation in this class was aseptic fill-finish capacity and injector pen assembly, the last steps, requiring large, highly regulated facilities that take years to build.

The result was a sustained shortage. Patients with type 2 diabetes could not fill prescriptions. Patients starting weight management therapy could not obtain it. Pharmacies rationed. And an enormous, visible, high-value demand went unmet.

What compounding is, and what the shortage permitted

Compounding is a legitimate and long-established pharmacy practice: preparing a medication tailored to an individual patient's needs — a different strength, a liquid form for someone who cannot swallow tablets, a formulation without an allergen. In the United States it operates under two categories. 503A facilities compound for individually identified patients pursuant to a prescription. 503B outsourcing facilities may produce larger batches without patient-specific prescriptions and are subject to more stringent manufacturing requirements.

Compounded products are not FDA-approved. They are not reviewed for safety or efficacy. The practice exists because individual patients sometimes need something the approved product does not provide, and the regulatory framework accepts a trade-off in oversight to permit it.

Critically for this story: U.S. law generally prohibits compounding a copy of a commercially available approved drug — but permits it when the drug appears on the FDA's drug shortage list. The shortage provision exists so that patients are not left without a needed medication when a manufacturer cannot supply.

Semaglutide went on the shortage list. The provision activated. And a very large market formed.

What the market looked like

The scale was substantial and it spanned an enormous range of legitimacy.

At one end: established 503B outsourcing facilities producing compounded semaglutide under significant quality systems, dispensed through clinicians, for patients who genuinely could not obtain the branded product.

At the other: telehealth operations whose business model was the prescription, marketing directly to consumers, with a physician encounter that in some cases was minimal; and sellers whose material's provenance was unclear.

And in between, a great deal that was hard to categorize from the outside.

Regulators raised several specific concerns, and they are worth separating because they are different kinds of problem:

Salt forms. Regulators warned that some compounded products used semaglutide salt forms — semaglutide sodium or semaglutide acetate — rather than the semaglutide base used in the approved products. These are not the same substance, their safety and efficacy had not been established, and their use fell outside what the compounding provisions permit.

Dosing errors. Compounded products were frequently supplied in vials requiring the patient to draw up a dose, rather than in a pre-filled pen delivering a fixed increment. Regulators and poison control centers reported errors, including substantial overdoses arising from confusion between units of measurement. This is a delivery-system failure rather than a drug failure, and it is a predictable consequence of removing an engineered device from a product that was designed around it.

Provenance. Concerns were raised about active ingredient sourced from suppliers not registered for pharmaceutical manufacture.

What happened when the shortage ended

Manufacturing capacity expanded. Supply improved. The FDA moved to remove semaglutide from the shortage list.

Which removed the legal basis for most compounding of it. The provision that had permitted copying a commercially available approved drug was contingent on the shortage, and when the shortage resolved, the permission narrowed — after transition periods, and amid litigation from parties with an interest in continuing.

The market did not vanish quietly. Some operations pivoted to related compounds, to combination products argued to be "personalized" and therefore outside the prohibition, or to jurisdictions with different rules. That pivot is itself informative about which participants were solving a supply problem and which had built a business.

⚠️ Hype Check — "compounded semaglutide is the same drug for less money"

This claim circulated widely and, like the best hype, it contains something true.

What's true: semaglutide is semaglutide. A legitimate 503B facility using genuine semaglutide base under real quality systems is producing a product with the same active molecule. During a genuine shortage, for a patient who could not otherwise obtain treatment, that was a real solution to a real problem. This is not a case where the skeptical position is simply correct.

What it obscures:

"The same drug" assumes the identity question is settled — and the salt-form warnings establish that for some products it was not. Semaglutide sodium is not semaglutide.

It ignores the delivery system. The approved product is a peptide plus a pen that delivers a defined dose. Removing the pen and substituting a vial and syringe is a change to the product, and the reported dosing errors are the predictable consequence. Chapter 4 argued that the delivery system is part of the drug; this is that argument in the field.

It ignores the variance. "Compounded semaglutide" named a category spanning genuine 503B production and material of unclear origin. A statement true of the best of it was applied to all of it.

And "for less money" is not a clinical claim. It was frequently the actual reason, and it is a legitimate consideration for a real person facing a real price — but it belongs in a conversation about access and cost (Chapter 12), not in a claim about equivalence.

Verdict: a true statement about part of a category, generalized to the whole, with the genuinely load-bearing question — is this vial what it says — left unaddressed.

Why this case is the anchor

Because it proves the cycle does not require a weak compound. Every other case in this chapter involves a compound whose human evidence is thin. This one has a Phase III program. The hype mechanism attached itself to a drug that works, and produced the same information degradation.

Because it demonstrates that the risk word is "unregulated," not "peptide." Nothing about semaglutide became more dangerous. What changed was the supply chain, the quality system, and the delivery device — and the documented harms track those changes rather than the molecule.

Because it shows a legitimate mechanism being used at unintended scale. The compounding shortage provision exists for good reasons and had, until then, mostly served its purpose. A drug with extraordinary demand and a supply constraint turned a narrow accommodation into a large market almost overnight. That is not a failure of anyone's intent; it is what happens when an exception meets an incentive of that size.

And because it complicates the moral story. Some people obtained compounded semaglutide because they could not get the branded product during a genuine shortage and had a genuine medical need. Some obtained it because it was cheaper and they could not afford the alternative. Some bought it from an operation that should not have been selling it. These are different situations and they do not share a verdict. Chapter 12 takes up the access and cost question properly, because it deserves better than a paragraph.

Discussion questions

1. The compounding shortage provision exists so patients are not left without needed medication. Semaglutide's shortage produced a market of unprecedented scale for that provision. Was the provision misused, correctly used at unexpected scale, or something else?

2. Regulators warned about semaglutide salt forms. Using Chapter 1, explain why "semaglutide sodium" is not straightforwardly "semaglutide," and why a consumer would have no way of knowing.

3. The approved product includes an engineered pen; compounded versions frequently did not. Chapter 4 argued the delivery system is part of the drug. Does the reported pattern of dosing errors support or complicate that claim?

4. Consider three people who used compounded semaglutide: one who could not obtain the branded drug during a genuine shortage; one who could obtain it but not afford it; one who wanted it for cosmetic weight loss and did not meet the approved criteria. Do they share a verdict? Should policy treat them identically?

5. When the shortage resolved, some operations pivoted to arguing their products were "personalized" and therefore outside the prohibition. What does this pivot reveal? Is the inference fair?

6. Compare to the four vials. Compounded semaglutide from a reputable 503B facility is which vial? From a telehealth operation with unclear sourcing? Does the categorization change how you would advise someone, and is that advice yours to give?